WO2026058153 - HPV-16 T CELL RECEPTOR USES AND COMPOSITIONS THEREOF
National phase entry is expected:
Publication Number
WO/2026/058153
Publication Date
19.03.2026
International Application No.
PCT/IB2025/059071
International Filing Date
09.09.2025
Title **
[English]
HPV-16 T CELL RECEPTOR USES AND COMPOSITIONS THEREOF
[French]
UTILISATIONS DE RÉCEPTEUR DE LYMPHOCYTES T DE VPH-16 ET COMPOSITIONS ASSOCIÉES
Applicants **
BIONTECH SE
Inventors
ARIETA, Christina
JUNEJA, Vikram
XIE, Yushu
MARTIN, Amber Marie
OMOKOKO, Tana
SROUJI, John
NEWRZELA, Sebastian
QUINKHARDT, Juliane
Priority Data
63/692,923
10.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 12145 | |
| EPO | Filing, Examination, Granting | 431211 | |
| Japan | Filing, Examination, Granting | 6314 | |
| South Korea | Filing, Examination, Granting | 22227 | |
| USA | Filing, Examination, Granting | 77090 |
Total:
548,987
Contact Us
Abstract[English]
The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of HPV associated disease or cancer.[French]
La présente divulgation concerne des récepteurs des lymphocytes T (TCR) dirigés contre des complexes peptide-CMH, des molécules d'acide nucléique isolées codant pour les TCR dirigés contre les complexes peptide-CMH, des lymphocytes T exprimant les TCR dirigés contre les complexes peptide-CMH, et des compositions pharmaceutiques destinées à être utilisées dans le traitement des maladies ou cancers associés au VPH.